Target intelligence / Profile preview

Left ventricular unloading

01

Overview

Left ventricular unloading refers to clinical and mechanical interventions—rather than an individual molecular species—aimed at reducing the mechanical workload of the left ventricle, typically in patients suffering from severe heart failure, cardiogenic shock, or following myocardial infarction. The aim is to decrease myocardial oxygen consumption, prevent adverse ventricular remodeling, and promote myocardial recovery by reducing left ventricular filling pressures and systemic afterload. Methods for LV unloading include pharmacologic agents such as ACE inhibitors, and more commonly mechanical circulatory support devices like the intra-aortic balloon pump, percutaneous ventricular assist devices (e.g., Impella), and extracorporeal membrane oxygenation (ECMO), among others. This process is monitored by assessing hemodynamic parameters and imaging to optimize myocardial function and prevent heart failure progression.

Other names
Left ventricular decompressionLV unloadingVentricular unloading
02

Mechanism of action

Pharmacological unloading: reduction of afterload and filling pressures using vasodilators or ACE inhibitors Mechanical unloading: use of devices such as intra-aortic balloon pump (IABP), Impella, LVAD, ECMO, percutaneous atrial septostomy, direct LV venting

03

Biological functions

Reduction of myocardial workDecrease in myocardial oxygen consumptionFavorable ventricular remodelingReduction in cardiac filling pressures (preload and afterload)Protection against ischemic injury and remodelingImproved cardiac output and hemodynamics
04

Disease associations

Cardiogenic shockAcute heart failureChronic heart failureMyocardial infarction (as adjunct to reperfusion therapy)Prevention/mitigation of ischemic heart failure
05

Safety considerations

Device-related complications ( bleeding, infection, vascular injury)Harlequin syndrome (with some devices/interventions)Potential for insufficient or excessive decompression; monitoring pressures and cardiac output is essentialThromboembolic riskRight ventricular dysfunction may complicate management
06

Interacting drugs

Angiotensin-converting enzyme (ACE) inhibitors (e.g., captopril)

2 more in the full profile.

07

Biomarkers

Pulmonary capillary wedge pressure (PCWP)Left ventricular end-diastolic pressure (LVEDP)Stroke volumeMyocardial oxygen consumptionEchocardiographic parameters of ventricular size/remodeling

Beyond the preview

Go deeper on Left ventricular unloading.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Left ventricular unloading.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call